LL-37
Also known as: Cathelicidin, hCAP18
An antimicrobial peptide with wound healing and immunomodulatory properties.
Overview
LL-37 is the only human cathelicidin antimicrobial peptide, derived from the C-terminus of hCAP18. It has broad antimicrobial activity and important roles in wound healing and immune regulation.
Mechanism of Action
Disrupts bacterial membranes through electrostatic interactions. Promotes wound healing by stimulating angiogenesis, keratinocyte migration, and growth factor release. Modulates immune response.
Pharmacokinetics
Local activity at wound sites. Susceptible to proteolytic degradation in serum.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Wound Healing
100-200 mcg
Once daily
2-4 weeks
Local application or injection near wound
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 1Broad-spectrum antimicrobial activity including antibiotic-resistant bacteria
- 2Enhanced wound closure in diabetic ulcer models
- 3Angiogenesis promotion and tissue regeneration
- 4Immunomodulatory effects in inflammatory conditions
Side Effects & Contraindications
Reported Side Effects
- Local irritation
- Redness at application site
Contraindications
- Known hypersensitivity
Safety Considerations
Generally well-tolerated topically. Systemic use data limited.
Storage Requirements
Store at -20C. Protect from light.
Scientific References
- 1